Global Leading Market Research Publisher QYResearch announces the release of its latest report “GDI2 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global GDI2 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for GDI2 Antibody was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. GDI2 Antibody’s immunogen is a synthetic peptide directed towards the C terminal region of human GDI2.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984581/gdi2-antibody
1. Core Market Dynamics: GDI2 Target Protein, Rab GTPase Regulation, and Vesicular Trafficking Research
Three core keywords define the current competitive landscape of the GDI2 Antibody market: GDI2 (GDP dissociation inhibitor 2, also known as Rab GDP dissociation inhibitor beta) , antibody validation for vesicular trafficking research (Rab GTPase cycle regulation) , and application versatility (IHC, IF, IP, WB, ELISA) . Unlike general research antibodies, GDI2 antibodies address specific scientific needs: (1) Rab GTPase regulation — GDI2 (along with GDI1) is a key regulator of Rab GTPases, extracting GDP-bound Rab from membranes and maintaining cytosolic Rab pools; (2) vesicular trafficking — GDI2 functions in endocytosis, exocytosis, and intracellular membrane trafficking; (3) neurological disorders — GDI2 implicated in intellectual disability, Alzheimer’s disease, Parkinson’s disease; (4) cancer — GDI2 dysregulated in breast, lung, and colorectal cancers; (5) infectious diseases — GDI2 involved in pathogen entry (viruses, bacteria). The immunogen is a synthetic peptide directed towards the C-terminal region of human GDI2 (a common strategy to generate specific antibodies). Researchers require validated antibodies for detection of GDI2 expression, subcellular localization (cytoplasmic), protein-protein interactions (with Rab GTPases), and quantification. The market is driven by cell biology funding, neuroscience research, and demand for reproducible research tools.
The solution direction for researchers involves selecting GDI2 antibodies based on three primary parameters: (1) Clonality : monoclonal (single epitope, high specificity, lot-to-lot consistency, recommended for IHC, IF, IP) vs. polyclonal (multiple epitopes, higher sensitivity, broader species reactivity, batch variability, recommended for WB, ELISA). (2) Application validation : manufacturers must provide validation data for specific applications: Western Blot (expected MW ~50-55 kDa), IHC (cytoplasmic staining), IF (cytoplasmic localization), IP (co-immunoprecipitation with Rab GTPases), ELISA (quantification). (3) Host species : rabbit (most common for polyclonal and monoclonal), mouse (monoclonal), recombinant (emerging, batch consistency).
2. Segment-by-Segment Analysis: Antibody Type and Application Channels
The GDI2 Antibody market is segmented as below:
Segment by Type
- Monoclonal Antibody (single epitope, high specificity, consistent)
- Polyclonal Antibody (multiple epitopes, high sensitivity, batch variation)
Segment by Application
- Immunochemistry (IHC) – tissue sections, disease studies
- Immunofluorescence (IF) – subcellular localization (cytoplasmic)
- Immunoprecipitation (IP) – protein-protein interaction with Rab GTPases
- Western Blot (WB) – protein expression analysis
- ELISA – quantification
- Others (flow cytometry, antibody arrays)
2.1 Clonality: Monoclonal Preferred for IHC/IP, Polyclonal for WB
Monoclonal GDI2 Antibodies (estimated 50-55% of GDI2 Antibody revenue) are recommended for IHC, IF, and IP applications where specificity and low background are critical. Monoclonals (mouse or rabbit) produced by hybridoma technology or recombinant methods. Rabbit monoclonals offer high affinity and low background. Key suppliers: Aviva Systems Biology (monoclonals), GeneTex (monoclonals), Thermo Fisher Scientific (Invitrogen, MA5 series), ABclonal Technology (rabbit monoclonals), Novus Biologicals (monoclonals), OriGene Technologies (monoclonals), Abcam (monoclonals, global leader), Proteintech Group (rabbit monoclonals). A case study from a cell biology lab (Q4 2025) used rabbit monoclonal GDI2 antibody (Proteintech, 1:150 for IHC-P) on human brain tissue sections. Strong cytoplasmic staining in neurons and glia. Antibody specificity validated by Western blot (single band at ~50 kDa) and GDI2 siRNA knockdown (signal loss).
Polyclonal GDI2 Antibodies (45-50% share) remain popular for: (1) Western Blot (high sensitivity for detecting endogenous GDI2); (2) species where monoclonals unavailable (rat, mouse, others); (3) cost-sensitive labs. Polyclonals produced by immunizing rabbits with synthetic peptide (C-terminal region of human GDI2) or recombinant protein. Batch variability is a concern. Key suppliers: LifeSpan BioSciences, EpiGentek, RayBiotech, Elabscience Biotechnology, Leading Biology, Affinity Biosciences, ProSci, Bioss, Bio-Rad (antibody division), Wuhan Fine Biotech, Biobyt, Jingjie PTM BioLab. A case study from a vesicular trafficking lab (Q3 2025) used polyclonal GDI2 antibody (LifeSpan, 1:1000 WB) to detect GDI2 in mouse brain lysates (cortex, hippocampus, cerebellum). Single band at ~50 kDa. Specificity validated by GDI2 knockdown in cell lines.
2.2 Application Channels: Western Blot Largest, IHC and IF Grow
Western Blot (WB) (estimated 30-35% of GDI2 Antibody revenue) is the largest application due to: (1) initial validation of antibody specificity (single band at expected MW ~50-55 kDa); (2) screening GDI2 expression across tissues (ubiquitous expression, high in brain, liver, kidney); (3) ease and low cost per sample. Expected band: 50-55 kDa (GDI2). Positive controls: HeLa, HEK293, mouse brain lysate, human liver lysate. Suppliers providing WB validation images command premium. A case study from a neuroscience lab (Q4 2025) used GDI2 antibody (WB, 1:500) to measure GDI2 protein levels in Alzheimer’s disease brain tissue (vs. control). No significant difference observed; GDI1 was downregulated.
Immunochemistry (IHC) (25-30% share) is the fastest-growing segment (projected CAGR 8-9% from 2026 to 2032), driven by: (1) tissue distribution studies (GDI2 expression in different organs); (2) neurological disease histology (Alzheimer’s, Parkinson’s); (3) cancer tissue studies. IHC requires antibodies validated for formalin-fixed paraffin-embedded (FFPE) sections, with antigen retrieval (citrate pH 6.0). IHC antibodies priced higher ($350-500/100µL). Suppliers with IHC validation: GeneTex (IHC validated), Thermo Fisher, Abcam, Proteintech, OriGene. A case study from a pathology lab (Q4 2025) performed IHC with monoclonal GDI2 antibody (Abcam, 1:100) on 100 breast cancer samples. Cytoplasmic GDI2 staining intensity correlated with tumor grade (p<0.01) and poor prognosis.
Immunofluorescence (IF) (15-20% share) used for subcellular localization (GDI2 primarily cytoplasmic, may co-localize with Rab GTPases). IF requires antibodies validated for paraformaldehyde-fixed, permeabilized cells. A case study from a cell biology lab (Q3 2025) performed IF with monoclonal GDI2 antibody (Thermo Fisher, 1:100) on HeLa cells, showing diffuse cytoplasmic staining with some perinuclear enrichment. Co-staining with Rab5 (early endosome marker) showed partial overlap (consistent with GDI2 function in Rab recycling).
Immunoprecipitation (IP) (10-15% share) used for co-IP to identify GDI2-interacting proteins (Rab GTPases (Rab1, Rab3, Rab5, Rab6, Rab8, Rab11)). IP requires high-affinity antibodies that bind native GDI2. Suppliers with IP validation: Aviva Systems Biology (IP validated), Thermo Fisher (IP validated), Abcam (IP validated), Bio-Rad (IP validated). A case study from a vesicular transport lab (Q4 2025) used GDI2 antibody (Aviva, IP) to pull down GDI2 from HeLa lysates; mass spectrometry identified multiple Rab GTPases (Rab1A, Rab5A, Rab6A, Rab8A, Rab11A) as interacting partners.
ELISA (5-10% share) for quantification of GDI2 protein in biological fluids or tissue lysates. ELISA requires matched antibody pairs. Limited availability; niche.
3. Industry Structure: Fragmented, Global Life Science Giants and Chinese Competitors
The GDI2 Antibody market is segmented as below by leading suppliers:
Major Players
- Aviva Systems Biology (USA) – Antibody manufacturer
- GeneTex (USA/Taiwan) – Antibody manufacturer
- LifeSpan BioSciences (USA) – Antibody and tissue array
- EpiGentek (USA) – Epigenetics and antibody
- Thermo Fisher Scientific (USA) – Global leader (Invitrogen, Pierce)
- ABclonal Technology (USA/China) – Antibody supplier
- RayBiotech (USA) – Antibody and array specialist
- Novus Biologicals (USA) – Antibody supplier (Bio-Techne)
- Elabscience Biotechnology (China/USA) – Chinese antibody manufacturer
- Leading Biology (USA) – Antibody supplier
- OriGene Technologies (USA/China) – Antibody, cDNA, protein
- Affinity Biosciences (China) – Antibody manufacturer
- ProSci (USA) – Antibody supplier
- Bioss (China/USA) – Antibody manufacturer
- Abcam (UK) – Global antibody leader (highly cited)
- Proteintech Group (USA/China) – Antibody specialist (validated, affordable)
- Bio-Rad (USA) – Life science reagents (antibody division)
- Wuhan Fine Biotech (China) – Antibody manufacturer
- Biobyt (China) – Reagent supplier
- Jingjie PTM BioLab (China) – PTM antibody specialist
A distinctive observation about the GDI2 Antibody market is the fragmentation (20 suppliers listed). Key players with strong GDI2 offerings include Abcam (global leader), Proteintech, Thermo Fisher, GeneTex, and Novus Biologicals. Chinese suppliers (Elabscience, Affinity, Bioss, ABclonal, Wuhan Fine, Biobyt, Jingjie PTM) offer lower-priced alternatives (150−300vs.150−300vs.300-600 for Western brands) and are gaining share in domestic and export markets. Barriers to entry moderate; synthetic peptide immunogens (C-terminal region) are a standard approach, allowing many suppliers to generate GDI2 antibodies.
4. Technical Challenges and Innovation Frontiers
Key technical challenges and innovation priorities in the GDI2 Antibody market include:
- Antibody specificity vs. GDI1: GDI1 and GDI2 (GDI alpha and beta) share ~70% sequence identity. Antibodies must be specific to GDI2 (not cross-react with GDI1). Validation by GDI2-specific siRNA/CRISPR knockdown is essential (GDI2 band disappears; GDI1 unchanged). Suppliers should provide specificity data.
- Immunogen design: The synthetic peptide directed towards the C-terminal region of human GDI2 is a common immunogen. This region may be less conserved across species (human vs. mouse) and may not recognize rodent GDI2. Researchers using mouse/rat models should check species reactivity.
- C-terminal epitope accessibility: C-terminal epitopes may be masked in fixed tissues (formalin cross-linking), affecting IHC/IF performance. Antibodies with N-terminal or internal epitopes may work better for FFPE IHC. Buyers should verify IHC validation data.
- Subcellular localization variability: GDI2 is predominantly cytoplasmic, but may translocate to membranes in certain conditions (interacting with membrane-bound Rab GTPases). IF studies should include appropriate controls.
5. Market Forecast and Strategic Outlook (2026-2032)
With projected growth driven by cell biology research (vesicular trafficking, Rab GTPase regulation), neuroscience (GDI2 in neurodevelopment and neurodegeneration), cancer research (GDI2 in tumor progression), and infectious disease research (pathogen entry mechanisms), the GDI2 Antibody market is positioned for moderate growth (projected 4-6% CAGR 2026-2030). Market stable but competitive; price pressure from Chinese suppliers and consolidation among global giants continue.
Strategic priorities for industry participants include: (1) for large suppliers (Abcam, Proteintech, Thermo Fisher): develop GDI2-specific antibodies with GDI1 cross-reactivity data; (2) recombinant monoclonal antibodies (batch consistency); (3) Chinese suppliers (Elabscience, Affinity, Bioss): invest in application validation (IHC-P, IF, IP) and publish data to compete globally; (4) develop matched antibody pairs for ELISA; (5) offer smaller trial sizes (10µL) for testing; (6) provide IHC-P optimization protocols and positive control recommendations (human brain, HeLa cells).
For buyers (researchers, core facilities, biotech/pharma R&D), GDI2 antibody selection criteria should include: (1) clonality (monoclonal for IHC/IP, polyclonal for WB); (2) application validation (WB, IHC-P, IF, IP) with images; (3) species reactivity (human, mouse, rat) and specificity vs. GDI1; (4) positive control recommendations (HeLa, HEK293, mouse brain lysate); (5) lot-to-lot consistency; (6) published citations; (7) price per test; (8) supplier reputation. For IHC on human tissue, monoclonal recommended; for WB screening, polyclonal acceptable if validated.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
